Eli Lilly’s planned regulatory approval for its oral weight-loss candidate orforglipron was pushed from January to April, following an undisclosed request for additional data from the agency. The delay prompted a 3.8% decline in Lilly’s share price on the first trading day after the announcement, erasing roughly $9 billion in market capitalization. Investors will be watching for further clinical or manufacturing details when the review clock restarts, as orforglipron is forecast to contribute up to $2.5 billion in peak annual sales if approved alongside existing injectable therapies.

Lilly and Nvidia committed $1 billion over five years to build and equip a joint R&D facility in California, combining Lilly’s drug data sets with Nvidia’s Vera Rubin AI processors. The lab, to be staffed by an equal mix of pharmaceutical and semiconductor experts, aims to accelerate early-stage target identification and in silico screening workflows. Management estimates that integrating high-performance computing could reduce lead discovery timelines by up to 40%, potentially lowering preclinical costs by more than $200 million annually once fully operational.

In phase 3 trials, Lilly’s novel triple-hormone agonist retatrutide achieved an average body-weight reduction of 28.7% over 68 weeks, outperforming the 26.6% seen with tirzepatide plus lifestyle intervention. Among participants with concurrent knee osteoarthritis, 12.3% reported complete resolution of joint pain by study end. Given the prevalence of osteoarthritis in the obesity population, analysts estimate that an added pain-relief label could expand retatrutide’s addressable market by 20%, supporting forecast peak sales of $5–7 billion annually beyond weight-management indications.